Spravato Treatment

Spravato (Esketamine) Nasal Spray, a Groundbreaking Therapy for Treatment Resistant Depression

What is Spravato?

Spravato is a prescription nasal spray approved by the FDA for adults with Treatment Resistant Depression and Major Depressive Disorder with acute suicidal ideation or behavior. Esketamine nasal spray Spravato for treatment resistant depression is a groundbreaking therapy that targets by blocking the NMDA receptor, which affects glutamate—a key neurotransmitter involved in mood regulation. This unique mechanism allows for rapid improvement in symptoms, often within hours to days.

Who is Eligible for Spravato?

Spravato is especially designed for patients suffering from Treatment Resistant Depression (TRD). If you are currently diagnosed with depression and have not been responsive to different oral antidepressants, you may be a good candidate for Spravato. This nasal spray should be taken along with an oral antidepressant in a certified healthcare setting, under supervision. Your healthcare provider determines eligibility based on your prior treatments and medical history.

How Spravato Works

Spravato is administered in a certified healthcare setting under the direct observation of a healthcare provider. Patients must be monitored for at least 2 hours after administration to manage potential risks such as sedation and dissociation. Torii is REMS certified and ensures the highest standards of care and safety.

Induction Phase: For new patients, Spravato is taken twice weekly for the first 4 weeks, followed by once weekly for the next 4 weeks. Patients are monitored for at least 2 hours after each dose due to possible side effects such as increased blood pressure, dissociation, or sedation. After the induction phase, treatment usually moves to a maintenance phase with less frequent dosing.

Maintenance Phase: The maintenence phase of Spravato treatment is designed to sustain the positive effects of the medication and prevent symptoms of returning. Spravato maintenance begins after the 4-week induction phase. The treatment schedule may vary based on individual needs, with sessions typically occurring once weekly or every other week.

Benefits of Spravato Treatment

Spravato can help reduce the symptoms of depression when you haven't seen much change with antidepressants.

Rapid Relief

Reduction of depressive symptoms within hours to days after the first dose in some patients.

FDA Approved

First new drug approved for depression by the Federal Drug Administration (FDA) in decades.

Safe and Supervised

You are safe in our REMS certified treatment center under the supervision of our medical experts.

Effective Care

Effective care by our well trained professionals at every step, from the time you enter our clinic.

Why Torii Wellness for Your Spravato Treatment?

Depression is no longer something to suffer through in silence. At Torii, your Spravato treatment center, we are committed to providing a safe, compassionate, and trustworthy environment for individuals living with Treatment-Resistant Depression (TRD).

Before beginning treatment, experienced medical professionals at our esketamine clinic conduct a comprehensive evaluation of your medical history and previous therapies to determine whether Spravato is an appropriate option for you. We take the time to clearly explain the treatment process, potential side effects, and any possible medication interactions so you can make an informed decision with confidence. During each administration at Torii Wellness Center, patients are closely monitored to ensure safety and comfort. While Treatment-Resistant Depression can feel overwhelming, the right support and evidence-based care can make meaningful change possible.

At Torii Wellness Center, our dedicated wellness team is committed to helping you move toward renewed hope, stability, and improved mental well-being.